Sugi Predict

Sugi Predict / Compounds / SCHEMBL5165136

SCHEMBL5165136

SCHEMBL5165136

[CH](Cc1ccccc1)SCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.52
▸ IDO1 P14902 4/20 0.41
▸ NOS3 P29474 1/20 0.41
▸ NOS1 P29475 1/20 0.41
▸ NOS2 P35228 1/20 0.41
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ ARG2 P78540 1/20 0.40
▸ CALM1 P0DP23 1/20 0.39
▸ CTSL P07711 1/20 0.39
▸ CTSB P07858 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CYP1A2 P05177 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ PRMT1 Q99873 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL934485 0.81 TP53 (0.44) MAOBIDO1NOS3NOS1NOS2
SCHEMBL8374192 0.79 MAOB (0.50) MAOBIDO1NOS3NOS1NOS2
SCHEMBL8374190 0.79 MAOB (0.50) MAOBIDO1NOS3NOS1NOS2
SCHEMBL8541497 0.79 MAOB (0.50) MAOBIDO1NOS3NOS1NOS2
SCHEMBL8374191 0.79 MAOB (0.50) MAOBIDO1NOS3NOS1NOS2
SCHEMBL11186271 0.78 TP53 (0.41) MAOBIDO1NOS3NOS1NOS2
SCHEMBL11452651 0.75 MAOB (0.52) MAOBIDO1NOS3NOS1NOS2
SCHEMBL2723228 0.75 MAOB (0.46) MAOBIDO1NOS3NOS1NOS2
SCHEMBL5644354 0.75 MAOB (0.52) MAOBIDO1NOS3NOS1NOS2
SCHEMBL3316547 0.75 MAOB (0.46) MAOBIDO1NOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 — — US claimed
EP-1678164-B1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORP (US) 2007-04-11 — — EP claimed
EP-1678146-A1 PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2006-07-12 — — EP claimed
EP-1678164-A1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2006-07-12 — — EP claimed
WO-2005105777-A1 SUBSTITUTED THIOPHENE AMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA & UPJOHN COMPANY LLC (US) 2005-11-10 — — WO claimed
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 — — US claimed
WO-2005040133-A1 PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-05-06 — — WO claimed
WO-2005037797-A1 SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-28 — — WO claimed
WO-2005035527-A1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-21 — — WO claimed
WO-2024148008-A1 TREATMENT OF NEUROENDOCRINE PROSTATE CANCER ORIC PHARMACEUTICALS, INC. (US) 2024-07-11 — — WO disclosed
US-20240228434-A1 PRODRUGS OF KV7 CHANNEL OPENERS CHATHAM BIOPHARMA CONSULTING, LLC 2024-07-11 — — US disclosed
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors MIRATI THERAPEUTICS INC (US) 2024-06-27 — — US disclosed
US-20240208896-A1 PRODRUGS OF KV7 CHANNEL OPENERS CHATHAM BIOPHARMA CONSULTING, LLC 2024-06-27 — — US disclosed
CN-118251218-A Combination therapy for treating cancer using PRMT5 inhibitors 米拉蒂医疗股份有限公司 2024-06-25 — — CN disclosed
EP-1678146-A1 PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2006-07-12 — — EP disclosed
WO-2005105777-A1 SUBSTITUTED THIOPHENE AMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA & UPJOHN COMPANY LLC (US) 2005-11-10 — — WO disclosed
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 — — US disclosed
WO-2005040133-A1 PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-05-06 — — WO disclosed
WO-2005037797-A1 SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-28 — — WO disclosed
WO-2005035527-A1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208896-A1 PRODRUGS OF KV7 CHANNEL OPENERS KCNA7, KCNB1, KCNB2 MAOB 323/4885IDO1 4143/4885NOS3 2444/4885
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors PRMT1, PRMT5, PRMT6 MAOB 3170/4885IDO1 1075/4885NOS3 2237/4885
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 MAOB 2923/4885IDO1 1519/4885NOS3 93/4885
US-20240228434-A1 PRODRUGS OF KV7 CHANNEL OPENERS KCNA7, KCNB1, KCNB2 MAOB 323/4885IDO1 4143/4885NOS3 2444/4885
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation CNKSR1, IL1RN, CHUK MAOB 3397/4885IDO1 2423/4885NOS3 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.